Lincoln Pharmaceuticals Ltd. (LINCOLN.BO)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in INR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | INR m | 3,768 | 4,147 | 4,682 | 5,050 | 5,805 | 6,232 | 6,710 | 6,710 |
| Operating profit | INR m | 832 | 832 | ||||||
| Net profit | INR m | 514 | 623 | 694 | 729 | 933 | 823 | 879 | 879 |
| EPS reported | INR | 43.88 | 43.89 | ||||||
| Operating cashflow per share | INR | 53.39 | 24.85 | ||||||
| Capex per share | INR | 12.69 | 5.37 | ||||||
| FCF per share | INR | 40.69 | 19.48 | ||||||
| Free cash flow | INR m | 815 | 390 | ||||||
| Net debt | INR m | -2,368 | -2,368 | ||||||
| Book value equity | INR m | 7,576 | 7,576 | ||||||
| Book value per share | INR | 378.2 | 378.3 | ||||||
| Number of shares | m | 20.03 | 20.03 | ||||||
| DPS (TTM paid) | INR | - | 3.60 |
Financial summary
Financials in INR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 12.86 | 14.10 | ||||||
| P/B LTM | x | 1.49 | 1.46 | ||||||
| P/S LTM | x | 1.69 | 1.65 | ||||||
| P/FCF LTM | x | 13.88 | 28.36 | ||||||
| EV/EBITDA LTM | x | 8.41 | 9.42 | ||||||
| EV/Sales LTM | x | 1.64 | 1.79 | ||||||
| Earnings Yield LTM | % | +7.78% | +7.09% | ||||||
| FCF Yield | % | +7.20% | +3.53% | ||||||
| Quality | |||||||||
| ROE | % | - | +12.29% | ||||||
| ROIC | % | +8.07% | +8.07% | ||||||
| Operating margin | % | +12.40% | +12.40% | ||||||
| Gross margin | % | +32.81% | +38.06% | ||||||
| FCF/Sales | % | +12.15% | +5.81% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +6.74% | -5.78% | ||||||
| Sales Growth YoY | % | +7.67% | +15.59% | ||||||
| Net Income Growth YoY | % | +6.74% | -5.80% | ||||||
| FCF Growth | % | +10.49% | +64.29% | ||||||
| Operating Profit Growth | % | -6.11% | -0.05% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +0.32% | +0.29% | ||||||
| Dividend Growth | % | 0.00% | +100.00% | ||||||
| Payout Ratio | % | - | +0.36% | ||||||
| FCF/Debt | x | 18.43 | 8.82 | ||||||
| Net Debt/EBITDA | x | -0.22 | -0.24 | ||||||
| EBIT/Net interest | x | 82.12 | 82.12 | ||||||
| Net debt/market cap | % | +0.39% | +0.36% | ||||||
| Net debt/Equity | x | -0.31 | -0.31 | ||||||
| Gross debt/equity | x | 0.01 | 0.01 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Operating from its headquarters in Ahmedabad, India, Lincoln Pharmaceuticals Ltd. is a well-established Indian enterprise dedicated to the production and commercialization of a diverse range of pharmaceutical products. The company's extensive therapeutic portfolio addresses numerous health concerns, offering solutions across areas such as cold and cough relief, infectious disease management (antibiotics, antifungals, antimalarials), pain alleviation, gastrointestinal health, dermatology, anti-diabetic and anti-hypertensive medications, gynecological treatments, and formulations for cardiovascular, central nervous system, and respiratory conditions, alongside a selection of branded generic drugs. Furthermore, Lincoln Pharmaceuticals maintains a significant international footprint, exporting its pharmaceutical offerings to approximately 60 nations worldwide, encompassing key markets in Europe, Canada, North and Latin America, Africa, and the Asia Pacific region. This pharmaceutical firm was originally incorporated in 1979.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Lincoln Pharmaceuticals Ltd. (LINCOLN.BO)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Operating from its headquarters in Ahmedabad, India, Lincoln Pharmaceuticals Ltd. is a well-established Indian enterprise dedicated to the production and commercialization of a diverse range of pharmaceutical products. The company's extensive therapeutic portfolio addresses numerous health concerns, offering solutions across areas such as cold and cough relief, infectious disease management (antibiotics, antifungals, antimalarials), pain alleviation, gastrointestinal health, dermatology, anti-diabetic and anti-hypertensive medications, gynecological treatments, and formulations for cardiovascular, central nervous system, and respiratory conditions, alongside a selection of branded generic drugs. Furthermore, Lincoln Pharmaceuticals maintains a significant international footprint, exporting its pharmaceutical offerings to approximately 60 nations worldwide, encompassing key markets in Europe, Canada, North and Latin America, Africa, and the Asia Pacific region. This pharmaceutical firm was originally incorporated in 1979.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free